Search

Wood biomass is the most abundant feedstock envisioned for the development of modern biorefineries. However, the cost-effective conversion of this form of biomass into commodity products is limited by its resistance to enzymatic degradation. Here we describe a new family of fungal lytic polysaccharide monooxygenases (LPMOs) prevalent among white-rot and brown-rot basidiomycetes that is active on xylans-a recalcitrant polysaccharide abundant in wood biomass. Two AA14 LPMO members from the white-rot fungus Pycnoporus coccineus substantially increase the efficiency of wood saccharification through oxidative cleavage of highly refractory xylan-coated cellulose fibers. The discovery of this unique enzyme activity advances our knowledge on the degradation of woody biomass in nature and offers an innovative solution for improving enzyme cocktails for biorefinery applications.

Although microalgae are a promising biobased feedstock, industrial scale production is still far off. To enhance the economic viability of large-scale microalgae processes, all biomass components need to be valorized, requiring a multi-product biorefinery. However, this concept is still too expensive. Typically, downstream processing of industrial biotechnological bulk products accounts for 20-40% of the total production costs, while for a microalgae multi-product biorefinery the costs are substantially higher (50-60%). These costs are high due to the lack of appropriate and mild technologies to access the different product fractions such as proteins, carbohydrates, and lipids. To reduce the costs, simplified processes need to be developed for the main unit operations including harvesting, cell disruption, extraction, and possibly fractionation., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

This article outlines the current context and the development of the European Bioeconomy Strategy. It analyses the current situation, challenges and needs for EU action and concludes with the next steps that the European Commission will undertake to review and update the Bioeconomy Strategy. Bioeconomy offers great opportunities to realising a competitive, circular and sustainable economy with a sound industrial base that is less dependent on fossil carbon. A sustainable bioeconomy also contributes to climate change mitigation, with oceans, forests and soils being major carbon sinks and fostering negative CO 2 emissions. The EU has invested significantly in research and innovation in this field and the European Commission is committed to lead on European bioeconomy strategy., (Copyright © 2017 Elsevier B.V. All rights reserved.)

This paper addresses recent government initiatives in biotechnology and various federal and regional initiatives. It presents an overview of the most visible industrial biotechnology projects under implementation and highlights changes in legislation affecting development of the bioeconomy in the Russian Federation., (Copyright © 2017. Published by Elsevier B.V.)

The bioeconomy transforms the fossil-based economy by forming new value chains and linking until now distinct industrial sectors. It provides an opportunity for rural as well as industrialized regions. The transformation process can be accelerated by building bioeconomy clusters comprising industries, academia and investors. Using the model of the German cluster CLIB2021 the role of cluster organisations and professional cluster management in moderating the transformation process and gaining a competetive advantage is discussed. In addition examples of how cluster management supports the formation of an industrial consortium and the analysis of regional options are presented., (Copyright © 2017 Elsevier B.V. All rights reserved.)

In recent years, the bioeconomy has established itself worldwide as a mainstay for achieving a sustainable economy. The targeted use of biological resources for industrial purposes can help to successfully reconcile ecology and economy in the long term. Like digitalization, biologization as the guiding principle of the bioeconomy has the potential to effect a fundamental change in industry. This change must be driven and supported by a committed research and innovation policy. The German Federal Government was one of the first governments worldwide to put the bioeconomy on its research policy agenda when it adopted the "National Research Strategy BioEconomy 2030" in 2010. The respective national policy strategy was published two years later. Since then we have been successfully implementing measures to establish the bioeconomy. Our research programme is currently being developed further. Our aim is to strengthen the biobased transformation process towards a sustainable economy and to attach special importance to innovative technologies. Furthermore, bioeconomy research policy will have to be aimed more strongly towards achieving international goals such as the Sustainable Development Goals (SDGs) and to showing what contribution the bioeconomy can make in this context. The success of the bioeconomy requires a societal discourse on how our society can reconcile economic growth and sustainability in future. This requires the adaptation and continued development of national agendas and initiatives as well as efficient international cooperation., (Copyright © 2017 Elsevier B.V. All rights reserved.)

The unique selectivity of enzymes, along with their remarkable catalytic activity, constitute powerful tools for transforming renewable feedstock and also for adding value to an array of building blocks and monomers produced by the emerging bio-based chemistry sector. Although some relevant biotransformations run at the ton scale demonstrate the success of biocatalysis in industry, there is still a huge untapped potential of catalytic activities available for targeted valorization of new raw materials, such as waste streams and CO 2 . For decades, the needs of the pharmaceutical and fine chemistry sectors have driven scientific research in the field of biocatalysis. Nowadays, such consolidated advances have the potential to translate into effective innovation for the benefit of bio-based chemistry. However, the new scenario of bioeconomy requires a stringent integration between scientific advances and economics, and environmental as well as technological constraints. Computational methods and tools for effective big-data analysis are expected to boost the use of enzymes for the transformation of a new array of renewable feedstock and, ultimately, to enlarge the scope of biocatalysis., (Copyright © 2017 Elsevier B.V. All rights reserved.)

During the Industrial Revolution, it became clear that wood was unsuited as an energy source for industrial production, especially iron smelting. However, the transition to coal was the effort of decades. Similarly, the transition from coal to oil was neither a smooth nor rapid process. The transition to an energy and materials production regime based on renewable resources can similarly be expected to be fraught with many setbacks and obstacles, technically and politically. Those earlier transitions, however, were not complicated by the so-called grand challenges faced today. Above energy security and food and water security lurks climate change. Some events of 2015 have politically legitimised climate change and its mitigation, and 2016 saw the world finally sworn to action. The bioeconomy holds some of the answers to the economic challenges thrown up by mitigating climate change while maintaining growth and societal wellbeing. For bioeconomy policy makers, the future is complex and multi-faceted. The issues start in regions and extend to global reach. It is hard to quantify what is going to be the most difficult of challenges. However, one of the visions for the bioeconomy, that of distributed manufacturing in small- and medium-scale integrated biorefineries flies in the face of the current reality of massive fossil fuel and petrochemical economies of scale, married to gargantuan fossil fuel consumption subsidies., (Copyright © 2017 Elsevier B.V. All rights reserved.)

In the last ten years, bioeconomy strategies and policy-related bioeconomy initiatives have been developed all over the world. Some of them are currently in the process of translation into specific actions. In most cases, the approaches followed have been top-down policy-related initiatives, triggered by the public sector originating a dynamic which can bring together different bioeconomy stakeholders i.e. industry, academia, financial operators and farmers. This article describes a bottom-up situation with unique bioeconomy-related features that deserve specific attention. Over the last 40 years, Almería, in the south east of Spain, has developed one of the most efficient agro-industrial complexes in the world, evolving from a traditional and subsistence agriculture, to becoming the major vegetable exporter in the European Union (EU). This growth set aside issues such as sustainability, long-term perspectives on water resources or agricultural waste. However, societal concerns about a circular economy, as well as policy initiatives in the EU and in Spain on bioeconomy are changing the situation towards an integrated, efficient and sustainable bioeconomy system. Currently, the production chain demands innovations related to the use of biomass as source of bioproducts and bioenergy in order to remain competitive. Some positive aspects are the relatively small size of the agro-industrial area, making transport and communications rapid and easy, and the existence of strong and dedicated academic and financial institutions. This article outlines the current efforts and initiatives to couple the existing successful agro-industrial complex with that of a fully sustainable bioeconomy model., (Copyright © 2017 Elsevier B.V. All rights reserved.)

The contribution of life sciences to the Knowledge-Based Bioeconomy (KBBE) asks for the transition of contemporary, gene-based biotechnology from being a trial-and-error endeavour to becoming an authentic branch of engineering. One requisite to this end is the need for standards to measure and represent accurately biological functions, along with languages for data description and exchange. However, the inherent complexity of biological systems and the lack of quantitative tradition in the field have largely curbed this enterprise. Fortunately, the onset of systems and synthetic biology has emphasized the need for standards not only to manage omics data, but also to increase reproducibility and provide the means of engineering living systems in earnest. Some domains of biotechnology can be easily standardized (e.g. physical composition of DNA sequences, tools for genome editing, languages to encode workflows), while others might be standardized with some dedicated research (e.g. biological metrology, operative systems for bio-programming cells) and finally others will require a considerable effort, e.g. defining the rules that allow functional composition of biological activities. Despite difficulties, these are worthy attempts, as the history of technology shows that those who set/adopt standards gain a competitive advantage over those who do not., (Copyright © 2017 Elsevier B.V. All rights reserved.)

Since 1990s Malaysia aspired to make biotechnology and bioeconomy as her engines of economic growth to utlise the abundance of natural resources and biodiversity. The public sector plays an integral role in developing the sector and various incentives are in place for the private sector to be actively involved and to forge collaboration with the public sector. The country launched its National Biotechnology Policy in 2005 and later launched its National Bioeconomy Programme in 2010 to become the first country in South East Asia and second in Asia after China to have such an initiative. Malaysia is also very proactive in its biosafety law and regulations and has most of the related legal instrument in place. A lot of success has been recorded since the inception of the National Biotechnology Policy in terms of job creation, contribution to GDP through biobusinesses and investment from foreign companies, but the sector is not spared from challenges too. Due to the nature of the discipline that is multidisciplinary and that requires huge amount of investment, expertise and political will, there are a lot of barriers before the country emerges as a bioeconomy player. This paper discusses the public policies, initiatives and funding mechanisms in place in Malaysia that drive its research, development and commercialisation in the area of biotechnology and bioeconomy. The authors also discuss the challenges faced in Malaysia in implementing the policies., (Copyright © 2017 Elsevier B.V. All rights reserved.)

This article outlines the potential of the development of bioeconomy in Poland in the context of the European Union (EU). The analyses take into account the concept of bioeconomy, the overview of documents referring to the bioeconomy in the EU, including policy frameworks and agendas. Many countries including Poland emphasise the importance of bioeconomy, but have not yet developed a complex strategy. The state of bioeconomy in Poland is characterised by the sectors of agriculture, forestry and food production, as well as parts of the chemical, biotechnology and energy industries. In 2014 the global production volume in the Polish bioeconomy amounted to PLN 343 billion with the sector employing almost 3 million staff. However, the structure of the bioeconomy is dominated by traditional sectors, such as agriculture and agro-food industries. This article presents the analysis of research and development activity in Poland from 2009 to 2015. It reports the position of Poland on GMOs and their future development potential. It is worth mentioning that many EU states including Poland have declared themselves as being "GMO-free countries"., (Copyright © 2017 Elsevier B.V. All rights reserved.)

Spain launched its own strategy on bioeconomy in January 2016 aiming at boosting a bioeconomy based on the sustainable and efficient production and use of biological resources. It highlights global societal challenges related with agricultural and biotechnological sciences in Spain and the great dynamism of the private sectors involved, particularly the agri-food, biotech and biomass sectors. The targeted sectors are food, agriculture and forestry, conditioned by water availability. It also includes the production of those industrial bioproducts and bioenergy obtained from the use and valorisation of wastes and residues and other non-conventional sources of biomass, in a circular economy. The strategy also puts a focus on rural and coastal development through several uses and services linked to ecosystems. The capacity to generate know-how in this area and the promotion of public and private collaboration are important pillars in order to enhance existing value chains and to create new ones. The strategy is led by R&I and Agriculture, Food and Environment policy managers and largely supported at regional level too. The strategic objective is the maintenance of the bioeconomy as an essential part of Spanish economy to contribute to the economic growth by creating new jobs and fostering investments., (Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.)

Five years following the publication of the EU Bioeconomy Strategy, this article discusses the state of play of the bioeconomy in Europe. Placing specific focus on Industrial Biotech, it outlines ten pragmatic recommendations from BIO-TIC [BIO-TIC, A roadmap to a thriving industrial biotechnology sector in Europe, 2015], an EU FP7 funded project completed in 2015 and coordinated by EuropaBio, comprehensively examining the hurdles to the development of a bioeconomy in Europe, enabled by industrial biotech. These include improving opportunities for feedstock producers within the bioeconomy; investigating the scope for using novel biomass; developing a workforce which can maintain Europe's competitiveness in industrial biotechnology; introducing a long-term, stable and transparent policy and incentive framework to promote the bioeconomy; improving public perception and awareness of industrial biotechnology and bio-based products; identifying, leveraging and building upon EU capabilities for pilot and demonstration facilities; promoting the use of co-products from processing; improving the bioconversion and downstream processing steps; improving access to financing for large-scale biorefinery projects; developing stronger relationships between conventional and non-conventional players., (Copyright © 2017. Published by Elsevier B.V.)

This article provides the authors' view on how Latin America has embraced bioeconomy principles in the last two decades with different levels of socio-economic impact. Examples of biodiversity resource valorization in medicine, eco-intensification of agriculture, biotechnology applications in mature sectors such as mining, food and beverage production, bio-refineries and ecosystem services are provided. The importance of participatory and social innovation initiatives is highlighted., (Copyright © 2017. Published by Elsevier B.V.)

To transform developing and least developing countries into industrialised ones, biotechnology could be deployed along the value chain, to provide support to the development of the bio-based industries in such a way to ensure sustainability of the sector and to reduce negative environmental impacts that might otherwise occur. In agribusiness development, for instance, interventions could start from inputs and agricultural mechanization, modern processing technologies, packaging of perishable products, the promotion of food safety in the processing and regulatory environment; and interventions to improve competitiveness and productivity. Worth over USD 300 billion in revenue, the role of the biotechnology goes beyond industrial growth, since it provides opportunities for progress towards many of the UN sustainable development goals (SDGs). This paper reviews the status of industrial biotechnology as it relates to inclusive and sustainable industrial development., (Copyright © 2017 Elsevier B.V. All rights reserved.)

A prime driver for a bioeconomy is the need to ensure the availability of sufficient biomass feedstock for food, feed, energy and industrial uses. This demand must be properly managed in the face of several challenges, including environmental changes and abrupt climate shifts. Plant breeding and breeding innovation is the cornerstone for sustainable supply of biomass. Not only does research and development in this sector aim at providing high yielding crops in order to maximize production, but R&D in this field will also allow to obtain highly specialized plant varieties with new or improved traits that fit to specific applications. At the same time, there is little awareness among the general public of the fact that state-of-the-art R&D is a prerequisite for the production of sufficient biomass of the right quality in a sustainable manner. Plant breeders in the EU have to grapple with a rather challenging policy and regulatory framework. An important way forward to overcome the existing impasse would be to ensure transparent and trustworthy communication with the general public., (Copyright © 2017 Elsevier B.V. All rights reserved.)

This article outlines the context and circumstances that favoured the development of a Bioeconomy Strategy in the European Union (EU) and the role played by the different Framework programmes for Research, Technological Development and Demonstration. Particular attention is given to the biotechnology related programmes and more specifically to the "Cell Factory" Key Action in the 5th Framework Programme (1998-2002). This, together with the parallel development of a Strategy on Biotechnology in 2002, served as a solid foundation for the creation of the, at the time, so-called Knowledge-Based Bio-Economy (KBBE). The KBBE concept emerged in 2005, a couple of years before the launch of the 7th Framework Programme (2007-2013). The experience accumulated over the years and the new societal expectations triggered the EU to launch a Strategy on Bioeconomy in 2012. This article concludes with a brief analysis of the two most important impacts of the EU Strategy on Bioeconomy. One is the Bioeconomy dedicated activity within the Programme Horizon 2020 (2014-2020), and the other the creation of a public-private partnership of bio-based industries. Both the impact of Horizon 2020 on the EU Bioeconomy Strategy and the bio-based industries public-private partnership are analysed in depth in two articles elsewhere in this volume., (Copyright © 2017 Elsevier B.V. All rights reserved.)

The cluster's policy initiated in France in 2005 was a formidable opportunity to boost innovation in the bioeconomy and to develop innovation platforms allowing industrial demonstration and feasibility at technology readiness level (TRL) from 5 to 9. The IAR Cluster (Industries and Agro-Resources), based in the Hauts-de-France and Grand Est regions is completely dedicated to the bioeconomy. IAR's work has contributed to build a complete innovation ecosystem on bioeconomy by opening up relationships between actors along the full value chain. It also facilitated investments in new platforms and programs through public-private partnerships. The Biorefinery of Pomacle is a good illustration of such a collective approach. The role of regional and national public partners is essential to succeed in this development which requires a long term strategy and support., (Copyright © 2017 Elsevier B.V. All rights reserved.)

With its vast population of over 1.4 billion, China is predicted soon to become the biggest single-country market in the world. The large population offers not only immense economic opportunity but also poses serious challenges related to resource depletion, pollution, and environmental degradation. To solve these burgeoning problems, biotechnology appears to be particularly well-positioned, since the Chinese government and large Chinese companies provide strong support towards the development of this field in terms both of policy and finance. Moreover, active research and commercial applications have led to rapid development of the Chinese bioindustry and bioeconomy. Chinese bioindustry is considered to be at the forefront of those of the developing and emerging countries and has added value to the country's economy and society. This study summarizes the development and current status of Chinese bioindustry, from research and development to recent market trends. It thus can be considered as a quick-glance resource for the various stakeholders in the biotechnology sector., (Copyright © 2017 Elsevier B.V. All rights reserved.)

Oligosaccharides are polymers with two to ten monosaccharide residues which have sweetener functions and sensory characteristics, in addition to exerting physiological effects on human health. The ones called nondigestible exhibit a prebiotic behavior being fermented by colonic microflora or stimulating the growth of beneficial bacteria, playing roles in the immune system, protecting against cancer, and preventing cardiovascular and metabolic issues. The global prebiotics market is expected to grow around 12.7% in the next 8 years, so manufacturers are developing new alternatives to obtain sustainable and efficient processes for application on a large scale. Most studied examples of biotechnological processes involve the development of new strategies for fructooligosaccharide, galactooligosaccharide, xylooligosaccharide, and mannanooligosaccharide synthesis. Among these, the use of whole cells in fermentation, synthesis of microbial enzymes (β-fructofuranosidases, β-galactosidases, xylanases, and β-mannanases), and enzymatic process development (permeabilization, immobilization, gene expression) can be highlighted, especially if the production costs are reduced by the use of agro-industrial residues or by-products such as molasses, milk whey, cotton stalks, corncobs, wheat straw, poplar wood, sugarcane bagasse, and copra meal. This review comprises recent studies to demonstrate the potential for biotechnological production of oligosaccharides, and also aspects that need more investigation for future applications in a large scale.

An industrial-scale, profitable method for production of the most widely used bioinsecticide, Bacillus thuringiensis (Bt), is challenging because of its widespread application. The aim of this study is to present a strategy to develop a low-cost, large-scale bioprocess to produce Bt H14. This study was first focused on the design of a culture medium composed of economical and available components, such as glycerol and lysed Saccharomyces cerevisiae. The production goal of 1200 ITU was achieved using a medium composed of 20:20 g L -1 of glycerol:lysed yeast in batch cultures. Efforts were subsequently focused on the design of an appropriate culture system, and an original two-stage culture system was proposed. First, yeast (the primary component of the culture medium) are cultivated using a minimal mineral medium and lysed, and in the second stage, Bt is cultivated in the same bioreactor using the lysed yeasts as culture medium (supplemented with a feeding pulse of 10 g L -1 glycerol). This system was called fed batch one pot (FOP). A new inoculation strategy is also presented in this study, since these Bt cultures were inoculated directly with heat pre-treated spores instead of vegetative bacteria to facilitate the bioprocess. This study was developed from the laboratory to production-scale bioreactors (measuring from 500 mL to 2500 L), and the efficiency of the proposed strategy was evident in LD 50 tests results, achieving 1796 ITU in large-scale processes. Both the use of non-conventional sources and the process development for biomass production are important for cost-effective production of Bt-based insecticides in mosquito control projects.

DNA nanotechnology, in particular DNA origami, enables the bottom-up self-assembly of micrometre-scale, three-dimensional structures with nanometre-precise features. These structures are customizable in that they can be site-specifically functionalized or constructed to exhibit machine-like or logic-gating behaviour. Their use has been limited to applications that require only small amounts of material (of the order of micrograms), owing to the limitations of current production methods. But many proposed applications, for example as therapeutic agents or in complex materials, could be realized if more material could be used. In DNA origami, a nanostructure is assembled from a very long single-stranded scaffold molecule held in place by many short single-stranded staple oligonucleotides. Only the bacteriophage-derived scaffold molecules are amenable to scalable and efficient mass production; the shorter staple strands are obtained through costly solid-phase synthesis or enzymatic processes. Here we show that single strands of DNA of virtually arbitrary length and with virtually arbitrary sequences can be produced in a scalable and cost-efficient manner by using bacteriophages to generate single-stranded precursor DNA that contains target strand sequences interleaved with self-excising 'cassettes', with each cassette comprising two Zn 2+ -dependent DNA-cleaving DNA enzymes. We produce all of the necessary single strands of DNA for several DNA origami using shaker-flask cultures, and demonstrate end-to-end production of macroscopic amounts of a DNA origami nanorod in a litre-scale stirred-tank bioreactor. Our method is compatible with existing DNA origami design frameworks and retains the modularity and addressability of DNA origami objects that are necessary for implementing custom modifications using functional groups. With all of the production and purification steps amenable to scaling, we expect that our method will expand the scope of DNA nanotechnology in many areas of science and technology.

Fulfilling the promise of marine biotechnology as a source for environmental and biomedical applications remains challenging. New technologies will be necessary to harness marine biodiversity, and collaboration across government, academic, and private sectors will be crucial to create mechanisms of technology transfer and promote the development of new marine biotechnology companies., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. Using data on publicly traded stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most comprehensive financial analysis of this sector to date. Our systematic exploration of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification method. We find that the performance of the biotech sector is highly sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high stock volatility. In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns consistently outperforming the market. The performance of all biopharmaceutical companies is subject not only to factors arising from their drug pipelines (idiosyncratic risk), but also from general economic conditions (systematic risk). The risk associated with returns has profound implications both for patterns of investment and for funding innovation in biomedical R&D.

Microalgae cultivation is a promising technology for integrated effluent polishing and biofuel production, but poor separability of microalgal cells hinders its industrial application. This study intended to selectively enrich settleable microalgal consortia in mixed culture by applying "wash-out" pressure, which was realized by controlling settling time (S T ) and volume exchange ratio (VER) in photo-SBRs. The results demonstrated that highly settleable microalgal consortia (settling efficiency>97%; SVI = 17-50 mL/g) could be enriched from indigenous algal cultures developed in WWTP's effluent. High VER was the key factor for the fast development of settleable microalgae. VER was also a controlling factor of the algal community structure. High VERs (0.5 and 0.7) resulted in the dominance of diatom, while low VER (0.2) facilitated the dominance of cyanobacteria. The settleable microalgal consortia were very efficient in phosphorus removal (effluent PO 4 3- -P<0.1 mg/L; removal efficiency>99%), which was largely attributed to intensive chemical precipitation of phosphate induced by high pH (8.5-10). However, the high pH decreased the bioavailable inorganic carbon, resulting in incomplete nitrate removal (effluent NO 3 - -N = 2.2-4 mg/L; removal efficiency = 61-79%) under high VERs and low lipid content (up to 10%) in the settleable microalgae. This problem could be resolved by sparging CO 2 or controlling pH. Overall, this study demonstrated a simple and effective method to overcome the separation challenge in scale-up of microalgae biotechnology for advanced wastewater purification and biofuel production., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Genomic medicine has greatly matured in terms of its technical capabilities, but the diffusion of genomic innovations worldwide faces significant barriers beyond mere access to technology. New global development strategies are sorely needed for biotechnologies such as genomics and their applications toward precision medicine without borders. Moreover, diffusion of genomic medicine globally cannot adhere to a "one-size-fits-all-countries" development strategy, in the same way that drug treatments should be customized. This begs a timely, difficult but crucial question: How should developing countries, and the resource-limited regions of developed countries, invest in genomic medicine? Although a full-scale investment in infrastructure from discovery to the translational implementation of genomic science is ideal, this may not always be feasible in all countries at all times. A simple "transplantation of genomics" from developed to developing countries is unlikely to be feasible. Nor should developing countries be seen as simple recipients and beneficiaries of genomic medicine developed elsewhere because important advances in genomic medicine have materialized in developing countries as well. There are several noteworthy examples of genomic medicine success stories involving resource-limited settings that are contextualized and described in this global genomic medicine innovation analysis. In addition, we outline here a new long-term development strategy for global genomic medicine in a way that recognizes the individual country's pressing public health priorities and disease burdens. We term this approach the "Fast-Second Winner" model of innovation that supports innovation commencing not only "upstream" of discovery science but also "mid-stream," building on emerging highly promising biomarker and diagnostic candidates from the global science discovery pipeline, based on the unique needs of each country. A mid-stream entry into innovation can enhance collective learning from other innovators' mistakes upstream in discovery science and boost the probability of success for translation and implementation when resources are limited. This à la carte model of global innovation and development strategy offers multiple entry points into the global genomics innovation ecosystem for developing countries, whether or not extensive and expensive discovery infrastructures are already in place. Ultimately, broadening our thinking beyond the linear model of innovation will help us to enable the vision and practice of genomics without borders in both developed and resource-limited settings.

This study quantifies the synergies between agriculture and bioenergy considering biodiesel production as part of a set of systemic initiatives. We present a case study in Ecuador taking into account the recent government measures aimed at developing the bioenergy sector. Four scenarios have been evaluated through a newly designed systemic scheme of circular-economy initiatives. These scenarios encompass three production pathways covering three energy crops: palm oil (PO), microalgae in open ponds (M1) and microalgae in laminar photobioreactors (M2). We have applied Benefit-Cost Analysis (BCA) methodology considering the Net Present Value (NPV) and the Benefit-Cost Ratio (BCR) as the main evaluation criteria. In terms of private investment, biodiesel production from PO is more attractive than from M2. However, regarding efficiency and effectiveness of public funds, M2 is superior to PO because the public BCR and NPV are higher, and the pressure on agricultural land is lower. Moreover, M2 as part of a systemic approach presents a better carbon balance. These findings show that, under a systemic approach based on circular economy, strategies like the one analyzed in this study are economically feasible and may have a promising future., (Copyright © 2016 Elsevier B.V. All rights reserved.)

Protein heterologous production offers viable opportunities to tailor laccase properties to specific industrial needs. The high redox potential laccase POXA1b from Pleurotus ostreatus was chosen as case study of marketable enzyme, due to its desirable properties in terms of activity/stability profile, and already assessed applicability. POXA1b was heterologously produced in Pichia pastoris by investigating the effect of inducible and constitutive expression systems on both the yield and the cost of its production. System performances were first assessed in shaken-flasks and then scaled-up in bioreactor. The production level obtained in the inducible system is 42U/mL, while the activity value achieved with the constitutive one is 60U/mL, the highest obtained in constitutive systems so far. The economic feasibility of recombinant laccase production was simulated, describing the case of an Italian small-medium enterprise. Two scenarios were evaluated: Scenario (I) production based on methanol inducible system; Scenario (II) production based on the constitutive system, fed with glycerol. At all the scales the glycerol-based fermentation is more economic than the methanol-based one. The price forecast for rPOXA1b production is 0.34€kU -1 for glycerol-based process, and is very competitive with the current price of commercial laccase., (Copyright © 2017 Elsevier B.V. All rights reserved.)

CO2 is a resource yet to be effectively utilized in the autotrophic biotechnology, not only to mitigate and moderate the anthropogenic influence on our climate, but also to steer CO2 sequestration for sustainable development and carbon neutral status. The atmospheric CO2 concentration has seen an exponential increase with the turn of the new millennia causing numerous environmental issues and also in a way feedstock crisis. To progressively regulate the growing CO2 concentrations and to incorporate the integration strategies to our existing CO2 capturing tools, all the influencing factors need to be collectively considered. The review article puts forth the change in perception of CO2 from which was once considered a harmful pollutant having deleterious effects to a renewable carbon source bearing the potential to replace the fossils as the carbon source through an autotrophic biorefinery. Here, we review the current methods employed for CO2 storage and capture, the need to develop sustainable methods and the ways of improving the sequestration efficiencies by various novice technologies. The review also provides an autotrophic biorefinery model with the potential to operate and produces a multitude of biobased products analogous to the petroleum refinery to establish a circular bioeconomy. Furthermore, fundamental and applied research niches that merit further research are delineated., (© FEMS 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Conjugated linoleic acid (CLA) has attracted as novel type of fatty acids having unusual health-promoting properties such as anticarcinogenic and antiobesitic effects. The present work employed castor oil as substrate for one-pot production of CLA using washed cells of Lactobacillus plantarum (L. plantarum) and lipases as catalysts. Among the screened lipases, the lipase Rhizopus oryzae (ROL) greatly assisted resting cells to produce CLA. Mass spectral analysis of the product showed that two major isomers of CLA were produced in the reaction mixture i.e. cis-9, trans-11 56.55% and trans-10, cis-12 43.45%. Optimum factors for CLA synthesis were found as substrate concentration (8 mg/mL), pH (6.5), washed cell concentration (12% w/v), and incubation time of 20 h. Hence, the combination of ROL with L. plantarum offers one pot production of CLA selectively using castor oil as a cost-effective substrate.

Microalgae serve as a promising source for the production of biofuels and bio-based chemicals. They are superior to terrestrial plants as feedstock in many aspects and their biomass is naturally rich in lipids, carbohydrates, proteins, pigments, and other valuable compounds. Due to the relatively slow growth rate and high cultivation cost of microalgae, to screen efficient and robust microalgal strains as well as genetic modifications of the available strains for further improvement are of urgent demand in the development of microalgae-based biorefinery. In genetic engineering of microalgae, transformation and selection methods are the key steps to accomplish the target gene modification. However, determination of the preferable type and dosage of antibiotics used for transformant selection is usually time-consuming and microalgal-strain-dependent. Therefore, more powerful and efficient techniques should be developed to meet this need. In this review, the conventional and emerging genome-editing tools (e.g., CRISPR-Cas9, TALEN, and ZFN) used in editing the genomes of nuclear, mitochondria, and chloroplast of microalgae are thoroughly surveyed. Although all the techniques mentioned above demonstrate their abilities to perform gene editing and desired phenotype screening, there still need to overcome higher production cost and lower biomass productivity, to achieve efficient production of the desired products in microalgal biorefineries., (© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)

Lignocellulosic biomass is an important feedstock for a potential future bio-based economy. Owing to its compact structure, suitable decomposition technologies will be necessary to make it accessible for biotechnological conversion. While chemical and enzymatic hydrolysis are currently established methods, a promising alternative is provided by fast pyrolysis. The main resulting product thereof, referred to as pyrolysis oil, is an energy-rich and easily transportable liquid. Many of the identified constituents of pyrolysis oil, however, have previously been reported to display adverse effects on microbial growth. In this Opinion we discuss relevant biological, biotechnological, and technological challenges that need to be addressed to establish pyrolysis oil as a reliable microbial feedstock for a bio-based economy of the future., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Reduced pesticide use is one of the reasons given by Europeans for accepting new genetic engineering techniques. According to the advocates of these techniques, consumers are likely to embrace the application of cisgenesis to apple trees. In order to verify the acceptability of these techniques, we estimate a Bayesian multilevel structural equation model, which takes into account the multidimensional nature of acceptability and individual, national, and European effects, using data from the Eurobarometer 2010 73.1 on science. The results underline the persistence of clear differences between European countries and whilst showing considerable defiance, a relatively wider acceptability of vertical gene transfer as a means of reducing phytosanitary treatments, compared to horizontal transfer.

Bacterial cellulose (BC) has received substantial attention because of its high purity, mechanical strength, crystallinity, liquid-absorbing capabilities, biocompatibility, and biodegradability etc. These properties allow BC to be used in various fields, especially in industries producing medical, electronic, and food products etc. A major discrepancy associated with BC is its high production cost, usually much higher than the plant cellulose. To address this limitations, researchers have developed several strategies for enhanced production of BC including the designing of advanced reactors and utilization of various carbon sources. Another promising approach is the production of BC from waste materials such as food, industrial, agricultural, and brewery wastes etc. which not only reduces the overall BC production cost but is also environment-friendly. Besides, exploration of novel and efficient BC producing microbial strains provides impressive boost to the BC production processes. To this end, development of genetically engineered microbial strains has proven useful for enhanced BC production. In this review, we have summarized major efforts to enhance BC production in order to make it a cost-effective biopolymer. This review can be of interest to researchers investigating strategies for enhanced BC production, as well as companies exploring pilot projects to scale up BC production for industrial applications., (Copyright © 2017 Elsevier B.V. All rights reserved.)

Our communication discusses the profound impact of bio-based economies - in particular microbial biotechnologies - on SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all. A bio-based economy provides significant potential for improving labour supply, education and investment, and thereby for substantially increasing the demographic dividend. This, in turn, improves the sustainable development of economies., (© 2017 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology.)

Government policies across the world seek to create clusters of companies and other stakeholders that specialise in a particular technology to build an 'industrial ecosystem'. This article looks at some examples of clusters created specifically with industrial biotechnology in mind and examines measures for policymakers., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Biotechnological production of vanillin is gaining momentum as the natural synthesis of vanillin that is very expensive. Ferulic acid (FA), a costly compound, is used as the substrate to produce vanillin biotechnologically and the making process is still expensive. Therefore, this study investigated the practical use of an agrobiomass waste, rice bran, and provides the first evidence of a cost-effective production of vanillin within 24 h of incubation using recombinant Pediococcus acidilactici BD16 (fcs + /ech + ). Introduction of two genes encoding feruloyl CoA synthetase and enoyl CoA hydratase into the native strain increased vanillin yield to 4.01 g L -1 . Bioconversion was monitored through the transformation of phenolic compounds. A hypothetical metabolic pathway of rice bran during the vanillin bioconversion was proposed with the inserted pathway from ferulic acid to vanillin and compared with that of other metabolic engineered strains. These results could be a gateway of using recombinant lactic acid bacteria for industrial production of vanillin from agricultural waste.

This paper investigates the impact of policies and institutions on health expenditures for a large panel of Organisation for Economic Co-operation and Development countries for the period of 2000-2010. A set of 20 policy and institutional indicators developed by the Organisation for Economic Co-operation and Development are integrated into a theoretically motivated econometric framework, alongside control variables related to demographic (dependency ratio) and non-demographic (income, prices and technology) drivers of health expenditures per capita. Although a large share of cross-country differences in public health expenditures can be explained by demographic and economic factors (around 71%), cross-country variations in policies and institutions also have a significant influence, explaining most of the remaining difference in public health spending (23%). Copyright © 2016 John Wiley & Sons, Ltd., (Copyright © 2016 John Wiley & Sons, Ltd.)